Radiopharm Theranostics

Corporate Governance

ASX Announcements

Updates

Home

Manrope

Click here to visit our dedicated Entitlement Offer (NREO) page for all the information you need to participate. 

Diamond Equity Research Radiopharm 13 December 2023 Update Note.pdf

We have updated our valuation model to account for the Q1 cash flow report and the recently concluded entitlement offering. Simultaneously, we have re-assessed the comparable company analysis, yielding a valuation of A$0.70 per share contingent on successful execution by the company.

Diamond Equity Research Update 13 Dec 2023